Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.3052W HIGH $3.48
Volume
21.07 K
Value Traded
2.06 M
Short % Float
19.13%
-3.49%Week
-10.27%1 Month
-5.68%3 Month
-14.87%6 Month
-82.59%5 Year
-82.59%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
503.37 M
EPS (TTM)
-0.40
P/E Ratio
-
Ent. Value
320.29 M
Total Shares
302.32 M
Float Shares
112.11 M
Insiders
46.34%
Institutions
26.15%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
PROK Catalyst Timeline
Dated clinical, regulatory and corporate events for ProKidney Corp.
Catalyst Timeline
Dated clinical, regulatory & corporate events for ProKidney Corp.
261Total events
17Upcoming
63Tier-1 (high impact)
2021 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Enrollment CompleteTrial
Completed enrollment of patients contributing to the Phase 3 PROACT 1 accelerated approval efficacy analysis
◆Enrollment CompleteRilparencelFiledTrial
Enrollment completion for PROACT 1 accelerated approval analysis
chronic kidney disease with type 2 diabetessource ↗
◆Enrollment MilestoneRilparencelFiledTrial
Complete enrollment for accelerated approval efficacy analysis (n=~360)
chronic kidney diseasesource ↗
◆Oral PresentationPresentation
ProKidney CEO to present at 44th Annual J.P. Morgan Healthcare Conference
▲PublicationRilparencelFiledPresentation
Phase 2 REGEN-007 results published in CJASN
chronic kidney disease with diabetessource ↗
▲Product LaunchRilparencelFiledPost-Market
Potential commercial launch in US after approval
diabetic chronic kidney diseasesource ↗
◆Interim AnalysisRilparencelFiledTrial
proact 2 interim anticipated
Diabetic Kidney Disease Stage 3/4source ↗
◆Poster PresentationRilparencelFiledPresentation
Poster on cell-specific inflammatory profile characterization of rilparencel at ASN Kidney Week 2025
chronic kidney diseasesource ↗
▲Full ResultsRilparencelFiledClinical Data
Full results from Phase 2 REGEN-007 trial presented at ASN Kidney Week 2025
advanced CKD and diabetessource ↗
▲Oral PresentationRilparencelFiledPresentation
Late-breaking clinical trials presentation at ASN Kidney Week 2025
advanced CKD and diabetessource ↗
▲Oral PresentationRilparencelFiledPresentation
Late-breaking clinical trial presentation at ASN Kidney Week
chronic kidney disease with diabetessource ↗
▲Late-BreakerRilparencelFiledPresentation
Positive Phase 2 REGEN-007 results presented as late-breaking at ASN Kidney Week
chronic kidney diseasesource ↗
◆Timing GuidanceRilparencelFiledPresentation
Interim data readout for REGEN-007 expected by Q4 2025
chronic kidney diseasesource ↗
◆Topline ReadoutRilparencelFiledClinical Data
Initial interim data from proact 2 Phase 3 study
chronic kidney diseasesource ↗
◆Interim AnalysisRilparencelFiledTrial
proact 2 interim results expected
diabetic chronic kidney diseasesource ↗
▲Enrollment UpdateRilparencelFiledTrial
More than half of patients required for accelerated approval analysis enrolled
chronic kidney disease with type 2 diabetessource ↗
▲Enrollment MilestoneRilparencelFiledTrial
More than half of required 360 patients enrolled for accelerated approval analysis
chronic kidney disease and diabetessource ↗
▲Enrollment UpdateRilparencelFiledTrial
More than half of required patients enrolled for accelerated approval analysis
advanced CKD and type 2 diabetessource ↗
▲Type B MeetingRilparencelFiledFDA Meeting
FDA Type B meeting confirmed accelerated approval pathway using eGFR slope as surrogate endpoint
chronic kidney disease with type 2 diabetessource ↗
▲Accelerated Approval PathwayRilparencelFiledDesignation
FDA alignment on accelerated approval pathway for rilparencel
chronic kidney disease with type 2 diabetessource ↗
▲Enrollment UpdateRilparencelFiledTrial
Enrolled nearly half of patients required for accelerated approval analysis
chronic kidney disease with type 2 diabetessource ↗
◆Oral PresentationPresentation
ProKidney management to participate in H.C. Wainwright 4th Annual Kidney Virtual Conference
▲Topline ReadoutRilparencelFiledClinical Data
Statistically significant and clinically meaningful positive topline results from full Group 1 mITT population of Phase 2 REGEN-007 trial
chronic kidney disease and diabetessource ↗
▲Type B MeetingRilparencelFiledFDA Meeting
FDA Type B meeting confirmed eGFR slope as surrogate endpoint for accelerated approval
chronic kidney disease and diabetessource ↗
▲FDA Feedback ReceivedRilparencelFiledFDA Meeting
FDA confirmed eGFR slope as acceptable surrogate endpoint for accelerated approval
advanced CKD and type 2 diabetessource ↗
◆Type B MeetingRilparencelFiledFDA Meeting
Planned Type B meeting with FDA to discuss accelerated approval pathway details
chronic kidney disease with diabetessource ↗
◆Full ResultsRilparencelFiledClinical Data
Full data from Group 1 of Phase 2 REGEN-007 study expected
chronic kidney disease with diabetessource ↗
◆Type B MeetingRilparencelFiledFDA Meeting
Planned Type B meeting with FDA to discuss accelerated approval pathway
chronic kidney disease with type 2 diabetessource ↗
▲Accelerated Approval PathwayRilparencelFiledDesignation
FDA agreed on accelerated approval pathway using eGFR slope as surrogate endpoint
chronic kidney diseasesource ↗
▲Late-BreakerRilparencelFiledPresentation
Positive Phase 2 REGEN-007 data presented as late-breaking clinical trial at ASN Kidney Week
chronic kidney diseasesource ↗
▲Enrollment MilestoneRilparencelFiledTrial
Generated significant enrollment momentum in Phase 3 PROACT 1 study
chronic kidney diseasesource ↗
●Manufacturing MilestoneRilparencelFiledCMC / Inspection
Initiated expansion of in-house manufacturing footprint in two adjacent facilities totaling 180,000 SF in Winston-Salem, NC
▲PublicationRilparencelFiledPresentation
Phase 2 REGEN-007 results published in CJASN
chronic kidney diseasesource ↗
◆Oral PresentationRilparencelFiledPresentation
Full results from REGEN-007 to be submitted to ASN 2025 Kidney Week as late-breaking clinical trial
chronic kidney disease and diabetessource ↗
◆Type B MeetingRilparencelFiledFDA Meeting
Upcoming FDA Type B meeting to confirm eGFR slope as surrogate endpoint for accelerated approval
chronic kidney disease and diabetessource ↗
▲Enrollment UpdateRilparencelFiledTrial
Significant enrollment momentum generated in Phase 3 PROACT 1 study
chronic kidney diseasesource ↗
Past FDA Catalysts and PDUFA Decisions
How PROK actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-06-30 | Rilparencel (REACT®) | Phase 2 data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C56 / 100
Pipeline Score
$2.0B
Pipeline Value
Undervalued
Valuation Signal
1
Drugs Scored
3.8x
rNPV / MCap
Top 11%
Micro Cap(rank 73 of 658)
Percentile Rank
ProKidney Corp. carries a moderate pipeline score (56/100), with $7.5B risk-adjusted pipeline value, led by Rilparencel in Type 2 Diabetes Mellitus (Phase 3), across $109B in total addressable markets.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Rilparencel Cell therapyNCT05099770 | Type 2 Diabetes Mellitus | Phase 3 | ACTIVE NOT_RECRUITING | 778 | Dec 1, 2029 |
Clinical Trial Results
Readouts, endpoints and source filings for every PROK program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Pereira Brian JGDirector | Sell | -222,948 | $1.42 | 08/20/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in PROK
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in PROK for Q2 2026. | ||||
PROK Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How PROK ranks across every disease it competes in
Competitive Position is a premium feature
See how PROK ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialPROK News
PROKProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2026
ProKidney Corp. announced the selection of eight abstracts for presentation at the American Society of Nephrology's Kidney Week 2026. The abstracts highlight the promising data on rilparencel, particularly its safety profile and potential to stabilize kidney function in patients with advanced chronic kidney disease and type 2 diabetes. The findings bolster confidence in the ongoing Phase 3 PROACT 1 study.
Read more →PROKProKidney Reports Second Quarter 2026 Financial Results and Business Highlights
ProKidney has successfully completed patient enrollment for the Phase 3 PROACT 1 study, which is crucial for the accelerated approval efficacy analysis. The company expects to release pivotal eGFR slope topline results in the second quarter of 2027. Additionally, ProKidney is on schedule to finish full enrollment for PROACT 1 in the latter half of 2026.
Read more →PROKProKidney Appoints Kenneth Locke as Chief Technical Officer
ProKidney Corp. has appointed Kenneth Locke as Chief Technical Officer to enhance its technical foundation as it prepares for a pivotal topline readout in Q2 2027. Locke brings extensive experience from Carisma Therapeutics and Celgene, where he led key manufacturing and regulatory functions. His leadership is expected to be vital as ProKidney advances its Phase 3 study for its autologous cell therapy targeting chronic kidney disease.
Read more →PROKProKidney Reports First Quarter 2026 Financial Results and Business Highlights
ProKidney Corp. reported its Q1 2026 financial results, highlighting progress in its Phase 3 PROACT 1 study for rilparencel, which is expected to complete enrollment by mid-2026. The company ended the quarter with $224.9 million in cash, supporting operations into mid-2027. Positive Phase 2 results were published, and FDA alignment on the accelerated approval pathway was confirmed.
Read more →PROKProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer
ProKidney Corp. has appointed Greg Madison as Chief Commercial Officer to lead the company's commercial strategy as it advances the cell therapy rilparencel towards potential commercialization. Madison brings over two decades of experience in biopharma, having previously held leadership roles at Shield Therapeutics and Keryx Biopharmaceuticals. His expertise in nephrology will be crucial as ProKidney aims to address unmet needs in chronic kidney disease treatment.
Read more →PROKProKidney Reports Full Year 2025 Financial Results and Business Highlights
ProKidney Corp. reported its financial results for 2025, highlighting significant progress in its Phase 3 PROACT 1 study for rilparencel, with completion of enrollment expected by mid-2026. The company has aligned with the FDA on an accelerated approval pathway, using eGFR slope as a surrogate endpoint. Financially, ProKidney ended 2025 with $270 million in cash, supporting operations into mid-2027.
Read more →PROKThis presentation includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. ProKidney's actual results m
ProKidney is advancing its Phase 3 trial for Rilparencel, an autologous cell therapy for chronic kidney disease (CKD), aiming for potential accelerated FDA approval. The company has reported promising results from earlier trials, indicating that this treatment could stabilize kidney function. However, numerous risks hang over their operations, including potential disruptions following domestication to the U.S. and difficulties in obtaining regulatory approvals. Expectations for a Biologics License Application submission are set for 2H 2027, with several essential milestones planned for 2026.
Read more →PROK▲ +5.1%on this news
ProKidney to Present at the 44th Annual J.P. Morgan Healthcare Conference
ProKidney Corp. announced that its CEO, Dr. Bruce Culleton, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The company, which focuses on chronic kidney disease (CKD) treatment through cell therapy, is expected to engage in one-on-one meetings with investors during the event. ProKidney's lead product, rilparencel, is currently undergoing a Phase 3 clinical trial aimed at preserving kidney function in patients with advanced CKD and type 2 diabetes.
Read more →PROKProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates
ProKidney Corp. reported its third quarter 2025 financial results, highlighting promising Phase 2 data for rilparencel in chronic kidney disease (CKD) patients. The FDA has confirmed that the eGFR slope can serve as a surrogate endpoint for accelerated approval. The company has sufficient cash to support operations through mid-2027, although it continues to incur significant losses.
Read more →PROKProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025
ProKidney Corp. presented full results from the Phase 2 REGEN-007 trial of rilparencel at ASN Kidney Week 2025. The data indicates that rilparencel may preserve kidney function in patients with advanced chronic kidney disease (CKD) and diabetes. This trial supports the ongoing Phase 3 PROACT 1 study, which aims to evaluate the efficacy of rilparencel further.
Read more →PROKProKidney to Participate in Two Upcoming Conferences: Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare Conference
ProKidney Corp. will participate in two significant healthcare conferences in November 2025. The Guggenheim Healthcare Innovation Conference will feature a fireside chat, while the Jefferies Global Healthcare Conference will include one-on-one meetings. These events aim to enhance investor engagement and showcase ProKidney's advancements in chronic kidney disease treatments.
Read more →PROK▲ +10.8%on this news
ProKidney Announces Two Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2025
ProKidney Corp. announced the acceptance of two abstracts for presentation at the American Society of Nephrology's Kidney Week 2025. This includes a late-breaking poster on the Phase 2 REGEN-007 study results. The event will take place from November 6-9, 2025, in Houston, TX, showcasing advancements in cellular therapy for chronic kidney disease.
Read more →PROKProKidney to Participate in Two Upcoming Conferences: the Citi Biopharma Back to School Conference and the Morgan Stanley Global Healthcare Conference
ProKidney Corp. will participate in the Citi Biopharma Back to School Conference and the Morgan Stanley Global Healthcare Conference in September. The company's management team will engage in discussions about their innovative cellular therapies for chronic kidney disease. ProKidney's lead product, rilparencel, is currently in a Phase 3 study aimed at preserving kidney function.
Read more →PROKProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates
ProKidney Corp. has reported positive developments regarding their treatment rilparencel for chronic kidney disease (CKD) and diabetes. The FDA has confirmed that estimated glomerular filtration rate (eGFR) slope is an acceptable surrogate endpoint for accelerated approval, a decision made in a recent Type B meeting. In an encouraging announcement, the company revealed a 78% improvement in eGFR slope during Phase 2 REGEN-007 and has successfully enrolled more than half of the patients needed for their Phase 3 PROACT 1 study. However, the company also reported a $37 million net loss for Q2 2025, impacting their financial outlook.
Read more →PROK▼ -8.7%on this news
ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel
ProKidney Corp. has confirmed alignment with the FDA on the accelerated approval pathway for its cellular therapy, rilparencel, aimed at treating chronic kidney disease (CKD). The FDA has accepted the eGFR slope as a surrogate endpoint for a Biologics License Application (BLA). ProKidney anticipates topline data readout in Q2 2027 and has nearly completed patient enrollment for the analysis.
Read more →PROK▲ +16.4%on this news
ProKidney to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference
ProKidney Corp. announced its participation in the H.C. Wainwright 4th Annual Kidney Virtual Conference. Senior management will engage in discussions about their advancements in cellular therapeutics for chronic kidney disease. The company's lead product, rilparencel, is under evaluation in Phase 2 and Phase 3 studies and has received FDA's RMAT designation.
Read more →PROK▲ +515%on this news· ran to +649% by day 3shared move
ProKidney Reports Statistically and Clinically Significant Topline Results for the Phase 2 REGEN-007 Trial Evaluating Rilparencel in Patients with Chronic Kidney Disease and Diabetes
ProKidney Corp. announced positive topline results from the Phase 2 REGEN-007 trial of rilparencel in patients with chronic kidney disease and diabetes. The trial demonstrated a statistically significant improvement in the estimated glomerular filtration rate (eGFR) slope. The company plans to present full results at the ASN 2025 Kidney Week and has an upcoming FDA Type B meeting to discuss accelerated approval pathways.
Read more →PROKProKidney Corp. Completes Domestication from the Cayman Islands to Delaware
ProKidney Corp. has successfully completed its domestication from the Cayman Islands to Delaware, effective July 1, 2025. This change was approved by shareholders at the Annual General Meeting on May 29, 2025. The company's Class A and Class B shares will now trade under the same symbols on Nasdaq, with no expected impact on operations.
Read more →PROKProKidney Reports First Quarter 2025 Financial Results and Business Highlights
ProKidney Corp. has reported its financial results for the first quarter of 2025, highlighting a cash position of $328.5 million, which supports operations until mid-2027. Key upcoming milestones include the anticipated full data from the Phase 2 REGEN-007 study in Q2 2025 and a regulatory update regarding the accelerated approval pathway for rilparencel. The company reported a net loss before noncontrolling interest of $38.0 million, a slight increase from the previous year. The focus remains on addressing chronic kidney disease through their innovative treatments involving rilparencel.
Read more →About ProKidney Corp.
Headquarters2000 FRONTIS PLAZA BLVD., WINSTON-SALEM, NC, 27103
BIOPHARMAWATCH ELITE PLUS
Trade the next PROK catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime